相关实验视频

Updated: Jul 12, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

针对具有临床相关EGFR突变的肺癌,使用抗EGFRRNA吸收酶

Brian J Thomas¹, Caitlyn Guldenpfennig¹, Yue Guan¹

¹Department of Molecular Microbiology and Immunology, Bond Life Sciences Center, University of Missouri School of Medicine, Columbia, MO 65211, USA.

Molecular therapy. Nucleic acids

|October 23, 2023

概括

这项研究表明,MinE07合酶有效向具有EGFR突变的非小细胞肺癌 (NSCLC) 细胞. MinE07显示出作为一种用于NSCLC识别的试剂的承诺,即使在体内也是如此.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物技术是生物技术.

背景情况:

非小细胞肺癌 (NSCLC) 通常涉及表皮生长因子受体 (EGFR) 突变.
在使用EGFR氨酸激酶抑制剂 (TKI) 时,耐药性会发展,需要采用替代向策略.
需要针对野生类型和突变EGFR的配体,以改善NSCLC治疗和药物输送.

研究的目的:

评估一种抗EGFR胺体MinE07对向NSCLC的潜力.
评估MinE07对各种EGFR突变的结合特性.
为了研究双特异性受体 (bsApt) 的有效性,将MinE07与针对NSCLC的抗c-Met受体结合起来.

主要方法:

在EGFR上MinE07结合位点的表征,包括与抗体表位点的重叠.
对具有常见致癌和耐药突变的EGFR变体结合的MinE07的评估.
对于NSCLC细胞和异种移植向的单特异性MinE07和双特异性受体 (bsApt) 的体外和体外评估.
不同标记的bsApt结构的生物分布研究.

主要成果:

MinE07结合点与EGFR上的临床相关抗体标重叠.
MinE07成功地与常见的致癌性和耐药性突变结合EGFR.
在bsApt证明了优越的体外NSCLC细胞标记,与单个特异性aptamers相比.
在体内双重向并没有提高NSCLC异种移植的识别能力,而不是单独使用MineE07.
在不同标记的bsApt配方之间观察到生物分布的显著差异.

结论:

在没有稳定的情况下,MinE07的阿巴胺配方可以有效地向异胎性肺癌.
MinE07显示出作为NSCLC的向试剂的潜力,特别是在具有临床相关EGFR突变的瘤中.
进一步开发针对NSCLC的基于aptamer的策略,有望为向治疗和药物输送提供希望.

关键词:

在EGFR的耐药性突变中.MT:交付策略的交付策略它们是Aptamers.生物分销生物分销分子工程分子工程是指分子工程.非小细胞肺癌的肺癌.氧核酸类的部分.有针对性的交付目标.瘤细胞表面受体的受体

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...